Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Upjohn INDs

Executive Summary

Company predicts seven IND applications will be filed before the end of 1990. Five INDs have been filed so far this year. Three were sent to FDA in January -- for U-73975, an antineoplastic, and trospectomycin vaginal cream and suppository for bacterial vaginosis; one in February, for the lazaroid U-76006F for spinal cord injury; and one in March, for the oral anticonvulsant compound U-54494A. An IND for the I.V. form of the drug is slated for filing in the third quarter, and Upjohn is forecasting the filing of soluble CD4-PE40 for AIDS in the fourth quarter of 1990. Another soluble CD4 (U-84796) will get an IND filing in the first quarter of 1991.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017523

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel